PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Progenics Pharmaceuticals Inc's account receivable for the three months ended in Jun. 2014 was $1.47 Mil. Progenics Pharmaceuticals Inc's revenue for the three months ended in Jun. 2014 was $1.48 Mil. Hence, Progenics Pharmaceuticals Inc's days sales outstanding for the three months ended in Jun. 2014 was 90.45.
Progenics Pharmaceuticals Inc's days sales outstanding increased from Jun. 2013 (63.16) to Jun. 2014 (90.45).
Days sales outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Account receivable can be measured by Days Sales Outstanding.
Progenics Pharmaceuticals Inc's Days Sales Outstanding for the fiscal year that ended in Dec. 2013 is calculated as
Progenics Pharmaceuticals Inc's Days Sales Outstanding for the quarter that ended in Jun. 2014 is calculated as:
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Progenics Pharmaceuticals Inc Annual Data
Progenics Pharmaceuticals Inc Quarterly Data